HK Stock Market Move | ZTO EXPRESS-W(02057) rises by over 4% again, "Double 11" business volume leads the industry, the company continues to expand market share.
Zhongtong Express (02057) rose by more than 4% again, with an increase of 4.12% at the time of writing, reaching 161.9 Hong Kong dollars, with a turnover of 62.3866 million Hong Kong dollars.
ZTO EXPRESS-W (02057) rose by more than 4%, rising by 4.12% to HK$161.9 as of the reporting date, with a turnover of HK$62.386 million.
In terms of news, on November 25, ZTO EXPRESS-W released the 2025 "Double 11" battle report. During this year's "Double 11" period (October 20 to November 21), ZTO Express ranked first in comprehensive assessment indicators on various platforms, with ZTO leading in reverse order volume, on-time pickup rate, and other specific service segments. In the delivery process, ZTO improved overall pickup and signing rate by 0.76% through data-driven strategies and end-to-end coordination, providing on-time and on-demand delivery services. In terms of "Double 11" business volume, ZTO Express continued to maintain its leading advantage, leading "Double 11" business volume for ten consecutive years. At the same time, ZTO's performance in the rural market was particularly impressive, with a year-on-year increase of 19.5% in rural express deliveries.
JP Morgan released a research report stating that ZTO EXPRESS-W will continue to be the preferred stock in the transportation industry in the next 3 to 6 months. JP Morgan cited the latest comments from ZTO Express management, indicating that the anti-internal competition policy is fundamentally reshaping the competitive landscape and shifting the entire industry's focus from a growth model based on volume to one that emphasizes quality and profitability. JP Morgan believes that ZTO Express is clearly benefiting from current industry developments, not only by expanding market share but also demonstrating steady profit performance.
Related Articles
.png)
From summit to win-win! FANGZHOU HEALTH (06086), VIGONVITA-B (02630) deepen strategic cooperation in the field of "AI + chronic disease management", jointly building the future of intelligent health industry.

HK Stock Market Move | CSTONE PHARMA-B (02616) rose more than 5%. The European Commission has approved a new indication for Sujigilibab.

HK Stock Market Move | HENLIUS (02696) rises more than 5%, multiple solid tumor pipelines will debut at the ESMO ASIA 2025 conference.
From summit to win-win! FANGZHOU HEALTH (06086), VIGONVITA-B (02630) deepen strategic cooperation in the field of "AI + chronic disease management", jointly building the future of intelligent health industry.
.png)
HK Stock Market Move | CSTONE PHARMA-B (02616) rose more than 5%. The European Commission has approved a new indication for Sujigilibab.

HK Stock Market Move | HENLIUS (02696) rises more than 5%, multiple solid tumor pipelines will debut at the ESMO ASIA 2025 conference.

RECOMMEND

Foreign Brands “Take On Chinese Names”: Starbucks And Burger King Change Hands As Chinese Capital’s Localization Scalpel Rewrites Global Rules
25/11/2025

Riding The Momentum Of Gemini 3, “Google Chain” Challenges “Nvidia Chain,” Reshaping The Ai Trading Landscape
25/11/2025

Silver Economy Accelerates As Personal Pension System Marks Three Years — Structural Changes Emerging
25/11/2025


